IPATential150 三期试验中接受伊帕塞替尼联合阿比特龙治疗患者的最终总生存期及与临床结局相关的分子数据
在 IPATential150 三期试验中,伊帕塞替尼联合阿比特龙未改善免疫组化 PTEN 缺失的转移性去势抵抗性前列腺癌患者的总生存期(分层 HR 0.94,95%CI 0.76-1.17,p=0.57),也未改善意向治疗人群的总生存期(分层 HR 0.91,95%CI 0.79-1.07,未正式检验)。探索性 NGS 分析发现基因组 PTEN 缺失或 PIK3CA/AKT1/PTEN 改变亚组可能从伊帕塞替尼获益,但需前瞻性研究进一步验证。
要点
- 伊帕塞替尼联合阿比特龙未改善免疫组化 PTEN 缺失患者的总生存期(分层 HR 0.94,95%CI 0.76-1.17,p=0.57)。
- 意向治疗人群总生存期亦无改善(分层 HR 0.91,95%CI 0.79-1.07,未正式检验)。
- 探索性 NGS 分析提示基因组 PTEN 缺失或 PIK3CA/AKT1/PTEN 改变亚组可能获益,需前瞻性验证。
核心结论
- 伊帕塞替尼联合阿比特龙未改善转移性去势抵抗性前列腺癌患者的总生存期,无论免疫组化 PTEN 状态如何。
- 探索性生物标志物分析发现基因组 PTEN 缺失或 PIK3CA/AKT1/PTEN 改变可能与 AKT 阻断的临床获益相关,需前瞻性研究进一步验证。
研究设计与样本
- 三期 IPATential150 试验,患者随机接受伊帕塞替尼(400 mg 每日一次)或安慰剂,所有患者均接受阿比特龙(1000 mg 每日一次)和泼尼松(5 mg 每日两次)。
- 在免疫组化 PTEN 缺失患者(n=521)和意向治疗人群(n=1101)中评估总生存期;探索性生物标志物分析包括二代测序检测 PTEN 状态及其他关键基因组改变。
主要发现
- 最终分析时中位随访 33.9 个月,免疫组化 PTEN 缺失患者(n=521)中伊帕塞替尼联合组与对照组的总体生存期分层 HR 为 0.94(95%CI 0.76-1.17;p=0.57),差异无统计学意义。
- 意向治疗人群(n=1101)中总体生存期分层 HR 为 0.91(95%CI 0.79-1.07),未正式检验。
- 探索性二代测序分析识别出基因组 PTEN 缺失亚组(n=208)和 PIK3CA/AKT1/PTEN 改变亚组(n=250),伊帕塞替尼联合组分别显示 HR 0.76(95%CI 0.54-1.07)和 HR 0.70(95%CI 0.51-0.96)。
局限性
- 分析为探索性。
- 二代测序数据不完整。
- 存在潜在的患者内异质性。
- 探索性生物标志物分析结果需前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: In the phase 3 IPATential150 trial, ipatasertib addition to abiraterone significantly reduced the risk of disease progression in men with metastatic castration-resistant prostate cancer (mCRPC) with PTEN loss on immunohistochemistry (IHC), but not in the intention-to-treat (ITT) population. Here we report the final overall survival (OS) analysis and present results for prespecified and exploratory biomarker analyses. METHODS: Patients were randomized to receive ipatasertib (400 mg once daily) or placebo. All patients received abiraterone (1000 mg once daily) and prednisone (5 mg twice daily). OS was assessed in patients with PTEN loss on IHC and the ITT population. Exploratory biomarker analyses included PTEN status via next-generation sequencing (NGS) and other key genomic alterations. KEY FINDINGS AND LIMITATIONS: At final analysis (median follow-up 33.9 mo), ipatasertib addition did not improve OS for patients with PTEN loss in IHC (n = 521; stratified hazard ratio [sHR] 0.94, 95% confidence interval [CI] 0.76-1.17; p = 0.57) or the ITT population (n = 1101; sHR 0.91, 95% CI 0.79-1.07; not formally tested). Exploratory NGS assessments identified subgroups with genomic PTEN loss (n = 208) or PIK3CA/AKT1/PTEN alterations (n = 250), with potentially better outcomes from ipatasertib (HR 0.76, 95% CI 0.54-1.07; and HR 0.70, 95% CI 0.51-0.96, respectively). Limitations include the exploratory nature of the analysis, incomplete availability of NGS data, and potential intrapatient heterogeneity. CONCLUSIONS AND CLINICAL IMPLICATIONS: Ipatasertib addition to abiraterone did not improve OS for men with mCRPC, regardless of PTEN status on IHC. Exploratory biomarker analyses identified additional genomic alterations of potential clinical relevance for AKT blockade in mCRPC that require further validation in prospective studies.
引用
- de Bono JS, He M, Shi Z, et al. Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. Eur Urol. 2025. PMID: 39884884. doi:10.1016/j.eururo.2024.12.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。